---
title: "Polaryx Therapeutics, Inc. (PLYX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PLYX.US.md"
symbol: "PLYX.US"
name: "Polaryx Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T22:45:50.199Z"
locales:
  - [en](https://longbridge.com/en/quote/PLYX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PLYX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PLYX.US.md)
---

# Polaryx Therapeutics, Inc. (PLYX.US)

## Company Overview

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [olaryx.com](https://olaryx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -22.37 | 210 | - | - | - |
| PB | 58.23 | 192 | 66.17 | 51.44 | 27.69 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-21T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.38 |
| Highest Target | 10.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PLYX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PLYX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PLYX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PLYX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**